<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:18:03Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7809592" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7809592</identifier>
        <datestamp>2021-01-21</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="pmc">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7809592</article-id>
              <article-id pub-id-type="pmcid">PMC7809592</article-id>
              <article-id pub-id-type="pmc-uid">7809592</article-id>
              <article-id pub-id-type="pmid">33443580</article-id>
              <article-id pub-id-type="pmid">33443580</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2020.31266</article-id>
              <article-id pub-id-type="publisher-id">zoi200977</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Infectious Diseases</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults</article-title>
                <subtitle>A Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Injection-Site Pain and Reactogenicity After Influenza Vaccination With aIIV3 vs HD-IIV3 in Older Adults</alt-title>
                <alt-title alt-title-type="running-head">Injection-Site Pain and Reactogenicity After Influenza Vaccination With aIIV3 vs HD-IIV3 in Older Adults</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Schmader</surname>
                    <given-names>Kenneth E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="zoi200977aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="zoi200977aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Christine K.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MSc</degrees>
                  <xref ref-type="aff" rid="zoi200977aff3">
                    <sup>3</sup>
                  </xref>
                  <xref ref-type="aff" rid="zoi200977aff4">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harrington</surname>
                    <given-names>Theresa</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH&amp;TM</degrees>
                  <xref ref-type="aff" rid="zoi200977aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rountree</surname>
                    <given-names>Wes</given-names>
                  </name>
                  <degrees>MPH</degrees>
                  <xref ref-type="aff" rid="zoi200977aff6">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Auerbach</surname>
                    <given-names>Heidi</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="zoi200977aff7">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Walter</surname>
                    <given-names>Emmanuel B.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref ref-type="aff" rid="zoi200977aff6">
                    <sup>6</sup>
                  </xref>
                  <xref ref-type="aff" rid="zoi200977aff8">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Barnett</surname>
                    <given-names>Elizabeth D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="zoi200977aff9">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schlaudecker</surname>
                    <given-names>Elizabeth P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref ref-type="aff" rid="zoi200977aff10">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Todd</surname>
                    <given-names>Chris A.</given-names>
                  </name>
                  <degrees>MPH</degrees>
                  <xref ref-type="aff" rid="zoi200977aff6">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Poniewierski</surname>
                    <given-names>Marek</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="zoi200977aff6">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Staat</surname>
                    <given-names>Mary A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref ref-type="aff" rid="zoi200977aff10">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wodi</surname>
                    <given-names>Patricia</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="zoi200977aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Broder</surname>
                    <given-names>Karen R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="zoi200977aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zoi200977aff1"><label>1</label>Center for the Study of Aging, Division of Geriatrics, Department of Medicine, Duke University School of Medicine, Durham, North Carolina</aff>
              <aff id="zoi200977aff2"><label>2</label>Geriatric Research Education and Clinical Center, Durham VA Health Care System, Durham, North Carolina</aff>
              <aff id="zoi200977aff3"><label>3</label>Section of Geriatrics, Division of Primary Care and Population Health, Stanford University, Stanford, California</aff>
              <aff id="zoi200977aff4"><label>4</label>Geriatric Research and Education Clinical Center, Palo Alto Veterans Affairs Health Care System, Palo Alto, California</aff>
              <aff id="zoi200977aff5"><label>5</label>Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia</aff>
              <aff id="zoi200977aff6"><label>6</label>Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina</aff>
              <aff id="zoi200977aff7"><label>7</label>Geriatrics Section, Boston Medical Center, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts</aff>
              <aff id="zoi200977aff8"><label>8</label>Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina</aff>
              <aff id="zoi200977aff9"><label>9</label>Section of Pediatric Infectious Diseases, Boston Medical Center, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts</aff>
              <aff id="zoi200977aff10"><label>10</label>Cincinnati Children’s Hospital and Medical Center, Department of Pediatrics Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> November 4, 2020.</p>
                <p content-type="published-online"><bold>Published:</bold> January 14, 2021. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2020.31266</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions">CC-BY License</ext-link>. © 2021 Schmader KE et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi200977cor1"><bold>Corresponding Author:</bold> Kenneth E. Schmader, MD, Center for Aging, Duke University Medical Center, PO Box 3003, Durham, NC 27705 (<email xlink:href="kenneth.schmader@duke.edu">kenneth.schmader@duke.edu</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions</bold><bold>:</bold> Dr Schmader had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Schmader, Harrington, Rountree, Auerbach, Walter, Barnett, Schlaudecker, Todd, Wodi, Broder.</p>
                <p><italic>Acquisition, analysis, or interpretation of data: </italic>All authors.</p>
                <p><italic>Drafting of the manuscript:</italic> Schmader, Liu, Harrington, Rountree, Todd, Broder.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content: </italic>All authors.</p>
                <p><italic>Statistical analysis:</italic> Harrington, Rountree, Schlaudecker, Poniewierski.</p>
                <p><italic>Obtained funding:</italic> Schmader, Harrington, Walter, Schlaudecker, Todd.</p>
                <p><italic>Administrative, technical, or material support:</italic> Schmader, Liu, Harrington, Auerbach, Walter, Barnett, Schlaudecker, Todd, Staat, Wodi, Broder.</p>
                <p><italic>Supervision:</italic> Schmader, Liu, Harrington, Auerbach, Walter, Schlaudecker, Todd, Staat.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Liu reported receiving grants from National Institute of Aging and National Center for Advancing Translational Sciences, National Institutes of Health during the conduct of the study. Dr Walter reported receiving grants from Pfizer to support clinical trial work as an investigator, and Moderna to support clinical trial work as an investigator outside the submitted work. Dr Barnett reported receiving honoraria from AAP Red Book Associate Editor Honorarium for this role and honoraria from Pfizer Support for serving as study site for multiple vaccine studies (COVID, RSV, PCV20; none are flu vaccine studies) outside the submitted work; and honoraria from UptoDate for topic on Immigrant Medicine; royalties from role as editor in Nelson's Antimicrobial Therapy; honoraria from role as editor of measles topic in BMJ Best Practice. Dr Poniewierski reported receiving grants from Amgen outside the submitted work. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This work was supported by the Centers for Disease Control and Prevention (Clinical Immunization Safety Assessment [CISA] project contracts 200-2012-53663/0008 and 200-2012-53663/0015 to Duke University and contract 200-2012-53709 to Boston University). Dr Schmader also received support from the National Institute on Aging, Duke Pepper Older Americans Independence Center (grant P30AG028716). Dr Schlaudecker also received support from the National Center for Advancing Translational Sciences of the National Institutes of Health, under award number 5UL1TR001425-04. Dr Liu also received support from the Department of Medicine at Boston University School of Medicine, the National Center for Advancing Translational Sciences/National Institutes of Health (grant 1KL2TR001411), and the National Institute of Aging (grant 1K23AG057813).</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The role of the funder included design and conduct of the study; analysis, preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p><bold>Disclaimer:</bold> The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref ref-type="supplementary-material" rid="note-ZOI200977-1-s">Supplement 3</xref>.</p>
                <p><bold>Additional Contributions:</bold> The authors acknowledge the contributions of the study participants and the following staff: Frank DeStefano, MD, MPH, Lisa Grohskopf, MD, MPH, Oidda Museru, MSN, MPH, Brendan Flannery, PhD, Tom Shimabukuro, MD, MPH, MBA, Pedro Moro, MD, MPH, and Devindra Sharma, MSN, MPH (Centers for Disease Control and Prevention); Sue Doyle, Kristen Gunnell, and Joyce Gandee (Duke University); Anisha Bhanot (Boston Medical Center); and Nancy Black, Brittney Cassell, and Krista Doerflein (Cincinnati Children’s Hospital and Medical Center). They were not compensated for their contributions.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2021-01-14T10:00">
                <day>14</day>
                <month>1</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>1</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>14</day>
                <month>1</month>
                <year>2021</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. -->
              <volume>4</volume>
              <issue>1</issue>
              <elocation-id>e2031266</elocation-id>
              <history>
                <date date-type="received">
                  <day>2</day>
                  <month>9</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>4</day>
                  <month>11</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2021 Schmader KE et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2031266.pdf">jamanetwopen-e2031266.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2020.31266"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi200977-1">
                  <title>Question</title>
                  <p>What are the comparative safety, reactogenicity, and short-term effects of vaccination on health-related quality of life after trivalent adjuvanted inactivated influenza vaccine (aIIV3) or trivalent high-dose inactivated influenza vaccine (HD-IIV3) in adults aged 65 years and older?</p>
                </sec>
                <sec id="ab-zoi200977-2">
                  <title>Findings</title>
                  <p>In this randomized clinical trial of 757 older adults (378 receiving aIIV3 and 379 receiving HD-IIV3), the proportion of participants with moderate-to-severe injection-site pain (primary outcome) was not higher after aIIV3 than HD-IIV3. No vaccine-related serious adverse events occurred, and postvaccination health-related quality of life was similar between aIIV3 and IIV3-HD groups.</p>
                </sec>
                <sec id="ab-zoi200977-3">
                  <title>Meaning</title>
                  <p>These findings suggest that from a safety standpoint, aIIV3 or HD-IIV3 is an acceptable option to prevent influenza in older adults.</p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser">
                <p>This randomized clinical trial assesses whether injection-site pain and reactogenicity are noninferior in trivalent adjuvanted inactivated influenza vaccine (aIIV3) compared with trivalent high-dose inactivated influenza vaccine (HD-IIV3) among adults aged 65 years and older.</p>
              </abstract>
              <abstract>
                <sec id="ab-zoi200977-4">
                  <title>Importance</title>
                  <p>Trivalent adjuvanted inactivated influenza vaccine (aIIV3) and trivalent high-dose inactivated influenza vaccine (HD-IIV3) are US-licensed for adults aged 65 years and older. Data are needed on the comparative safety, reactogenicity, and health-related quality of life (HRQOL) effects of these vaccines.</p>
                </sec>
                <sec id="ab-zoi200977-5">
                  <title>Objective</title>
                  <p>To compare safety, reactogenicity, and changes in HRQOL scores after aIIV3 vs HD-IIV3.</p>
                </sec>
                <sec id="ab-zoi200977-6">
                  <title>Design, Setting, and Participants</title>
                  <p>This randomized blinded clinical trial was a multicenter US study conducted during the 2017 to 2018 and 2018 to 2019 influenza seasons. Among 778 community-dwelling adults aged at least 65 years and assessed for eligibility, 13 were ineligible and 8 withdrew before randomization. Statistical analysis was performed from August 2019 to August 2020.</p>
                </sec>
                <sec id="ab-zoi200977-7">
                  <title>Interventions</title>
                  <p>Intramuscular administration of aIIV3 or HD-IIV3 after age-stratification (65-79 years; ≥80 years) and randomization.</p>
                </sec>
                <sec id="ab-zoi200977-8">
                  <title>Main Outcomes and Measures</title>
                  <p>Proportions of participants with moderate-to-severe injection-site pain and 14 other solicited reactions during days 1 to 8, using a noninferiority test (5% noninferiority margin), and serious adverse events (SAE) and adverse events of clinical interest (AECI), including new-onset immune-mediated conditions, during days 1 to 43. Changes in HRQOL scores before and after vaccination (days 1, 3) were also compared between study groups.</p>
                </sec>
                <sec id="ab-zoi200977-9">
                  <title>Results</title>
                  <p>A total of 757 adults were randomized, 378 to receive aIIV3 and 379 to receive HD-IIV3. Of these participants, there were 420 women (55%) and 589 White individuals (78%) with a median (range) age of 72 (65-97) years. The proportion reporting moderate-to-severe injection-site pain, limiting or preventing activity, after aIIV3 (12 participants [3.2%]) (primary outcome) was noninferior compared with HD-IIV3 (22 participants [5.8%]) (difference −2.7%; 95% CI, −5.8 to 0.4). Ten reactions met noninferiority criteria for aIIV3; 4 (moderate-to-severe injection-site tenderness, arthralgia, fatigue, malaise) did not. It was inconclusive whether these 4 reactions occurred in higher proportions of participants after aIIV3. No participant sought medical care for a vaccine reaction. No AECI was observed. Nine participants had at least SAE after aIIV3 (2.4%; 95% CI,1.1% to 4.5%); 3 had at least 1 SAE after HD-IIV3 (0.8%; 95% CI, 0.2% to 2.2%). No SAE was associated with vaccination. Changes in prevaccination and postvaccination HRQOL scores were not clinically meaningful and not different between the groups.</p>
                </sec>
                <sec id="ab-zoi200977-10">
                  <title>Conclusions and Relevance</title>
                  <p>Overall safety and HRQOL findings were similar after aIIV3 and HD-IIV3, and consistent with prelicensure data. From a safety standpoint, this study’s results support using either vaccine to prevent influenza in older adults.</p>
                </sec>
                <sec id="ab-zoi200977-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03183908?term=NCT03183908">NCT03183908</ext-link></p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI200977">
              <title>Introduction</title>
              <p>Older adults are at high risk for severe influenza illness, cardiovascular events, hospitalization, functional decline, and death following influenza infection.<sup><xref rid="zoi200977r1" ref-type="bibr">1</xref>,<xref rid="zoi200977r2" ref-type="bibr">2</xref>,<xref rid="zoi200977r3" ref-type="bibr">3</xref>,<xref rid="zoi200977r4" ref-type="bibr">4</xref>,<xref rid="zoi200977r5" ref-type="bibr">5</xref>,<xref rid="zoi200977r6" ref-type="bibr">6</xref>,<xref rid="zoi200977r7" ref-type="bibr">7</xref>,<xref rid="zoi200977r8" ref-type="bibr">8</xref>,<xref rid="zoi200977r9" ref-type="bibr">9</xref>,<xref rid="zoi200977r10" ref-type="bibr">10</xref></sup> Hospitalization rates for laboratory confirmed influenza are up to 10 times higher in people aged 65 years or older compared with younger adults.<sup><xref rid="zoi200977r1" ref-type="bibr">1</xref></sup> An estimated 71% to 90% of deaths from influenza occur in adults aged 65 years or older.<sup><xref rid="zoi200977r7" ref-type="bibr">7</xref>,<xref rid="zoi200977r8" ref-type="bibr">8</xref></sup> The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommends annual vaccination with any US-licensed, age-appropriate, influenza vaccine.<sup><xref rid="zoi200977r11" ref-type="bibr">11</xref></sup> In the US, influenza vaccines that are licensed for use only in persons aged 65 years and older are trivalent high-dose inactivated influenza vaccine (HD-IIV3 [Fluzone<sup>®</sup> High-Dose, licensed 2009]<sup><xref rid="zoi200977r12" ref-type="bibr">12</xref></sup>), trivalent adjuvanted inactivated influenza vaccine (aIIV3 [Fluad<sup>®</sup>, licensed 2015]<sup><xref rid="zoi200977r13" ref-type="bibr">13</xref></sup>), quadrivalent high-dose inactivated influenza vaccine (HD-IIV4 [Fluzone<sup>®</sup> High-Dose Quadrivalent, licensed 2019]<sup><xref rid="zoi200977r14" ref-type="bibr">14</xref></sup>), and quadrivalent inactivated adjuvanted influenza vaccine (aIIV4 [Fluad<sup>®</sup> Quadrivalent, licensed 2020]<sup><xref rid="zoi200977r15" ref-type="bibr">15</xref></sup>).</p>
              <p>During the 2020 to 2021 influenza season, it is anticipated that HD-IIV4 will replace HD-IIV3.<sup><xref rid="zoi200977r11" ref-type="bibr">11</xref>,<xref rid="zoi200977r16" ref-type="bibr">16</xref></sup> Both aIIV4 and aIIV3 products are expected to be distributed during the 2020 to 2021 influenza season.<sup><xref rid="zoi200977r11" ref-type="bibr">11</xref></sup> In addition to these age-specific vaccines, quadrivalent standard-dose, unadjuvanted inactivated influenza vaccines (SD-IIV4) and quadrivalent recombinant influenza vaccine (RIV4) are licensed and recommended for people aged 65 years and older.<sup><xref rid="zoi200977r11" ref-type="bibr">11</xref></sup></p>
              <p>Studies have observed modestly higher effectiveness of HD-IIV3 and aIIV3 compared with trivalent standard-dose, unadjuvanted inactivated influenza vaccines (SD-IIV3).<sup><xref rid="zoi200977r17" ref-type="bibr">17</xref>,<xref rid="zoi200977r18" ref-type="bibr">18</xref></sup> A study of Medicare beneficiaries aged 65 years and older observed that nearly three-quarters of vaccinees received aIIV3 or HD-IIV3 during the 2017 to 2018 influenza season.<sup><xref rid="zoi200977r19" ref-type="bibr">19</xref></sup> Safety and reactogenicity of these vaccines may also be a factor in the choice of vaccine. aIIV3 and HD-IIV3 have higher proportions of some local and systemic reactions compared with SD-IIV3.<sup><xref rid="zoi200977r20" ref-type="bibr">20</xref>,<xref rid="zoi200977r21" ref-type="bibr">21</xref></sup> Safety of aIIV3 and HD-IIV3 has not been compared directly in the same clinical trial in the US, nor has the relative impact of aIIV3 and HD-IIV3 reactions on short-term, postvaccination health-related quality of life (HRQOL) in older adults.</p>
              <p>We performed a clinical trial to determine comparative safety, reactogenicity, and short-term effects of vaccination on HRQOL after aIIV3 or HD-IIV3 in adults aged 65 years or older. The primary objective (statistical end point) was to compare proportions of participants with moderate-to-severe injection-site pain following aIIV3 vs HD-IIV3. A coprimary objective was to compare serious adverse events (SAEs) and adverse events of clinical interest (AECI) after each vaccine. Secondary objectives were to compare proportions of local and systemic reactions and changes in HRQOL after aIIV3 and HD-IIV3 vaccination.</p>
            </sec>
            <sec id="H1-2-ZOI200977">
              <title>Methods</title>
              <sec id="H2-1-ZOI200977">
                <title>Study Design and Participants</title>
                <p>We conducted a prospective, randomized, blinded clinical trial at CDC-sponsored Clinical Immunization Safety Assessment (CISA) Project<sup><xref rid="zoi200977r22" ref-type="bibr">22</xref></sup> centers during the 2017 to 2018 (Duke University Medical Center and Boston Medical Center) and 2018 to 2019 (Duke, Boston, and Cincinnati Children’s Hospital Medical Center) influenza seasons. The study protocol was approved by institutional review boards at each study site; CDC relied on the Duke institutional review board. Participants provided written informed consent. The trial protocol and statistical analysis plan are provided in <xref ref-type="supplementary-material" rid="note-ZOI200977-1-s">Supplement 1</xref>. This study followed the Consolidated Standards of Reporting Trials (<ext-link ext-link-type="uri" xlink:href="http://www.equator-network.org/reporting-guidelines/consort/">CONSORT</ext-link>) reporting guideline.</p>
                <p>Eligibility criteria included age greater than or equal to 65 years, living in the community, no immunosuppression as a result of an underlying illness or treatment, no use of anticancer chemotherapy or radiation therapy within the preceding 12 months, without dementia, able to speak English, and no contraindications to influenza vaccination (all criteria in eAppendix 1 in <xref ref-type="supplementary-material" rid="note-ZOI200977-1-s">Supplement 2</xref>). We aimed to have at least 20% of enrolled participants be aged 80 years or older.</p>
                <p>After obtaining written informed consent on day 1, study staff screened potential participants for cognitive impairment with the Mini-Cog test.<sup><xref rid="zoi200977r23" ref-type="bibr">23</xref></sup> Staff administered the Rowland Universal Dementia Assessment Scale (RUDAS) to adults whose Mini-Cog score was 2, which is considered a borderline score for dementia.<sup><xref rid="zoi200977r23" ref-type="bibr">23</xref>,<xref rid="zoi200977r24" ref-type="bibr">24</xref></sup> Persons who scored 23 or higher (range, 0-30) on the RUDAS were deemed eligible. Staff collected demographic, medical history, medication, and influenza immunization information on each participant. Race/ethnicity was defined by the participants. Participants were randomized (1:1) to receive aIIV3 or HD-IIV3 using a permuted block randomization scheme stratified by study site. Separate permuted blocks were used for participants aged 65 to 79 years and at least 80 years. Participants and study staff performing data collection and analysis were blinded to treatment allocation. Because there was a visual difference between aIIV3 and HD-IIV3, staff who prepared and administered study vaccines were unblinded but did not participate in data collection, outcome measurement, or analysis.</p>
                <p>Following randomization, a 0.5 mL intramuscular dose of either egg-based, US-licensed aIIV3 or HD-IIV3 was administered in the deltoid muscle. Each aIIV3 dose contained 15 µg of hemagglutinin (HA) from each of the 3 recommended influenza strains for the respective season and MF59 adjuvant, a squalene-based, oil-in-water emulsion. Each HD-IIV3 dose contained 60 µg of HA from each of the 3 recommended influenza strains for the respective season.</p>
              </sec>
              <sec id="H2-2-ZOI200977">
                <title>Safety and Reactogenicity Assessments</title>
                <p>Study staff monitored participants in the clinic for at least 15 minutes postvaccination for adverse events, including anaphylaxis and syncope, and assessed solicited reactogenicity events and unsolicited adverse events after vaccination on day 1 (vaccination day) through day 8 using a standard symptom diary. Local reactions assessed included injection-site pain, tenderness, swelling, redness, and shoulder pain on the vaccination side. Systemic reactions assessed were fatigue, malaise, myalgia, headache, arthralgia, nausea, vomiting, diarrhea, fever, and chills. Participants received a study thermometer, ruler, and education about completing the diary. Participants then self-graded the severity of their reactions. Reaction severity was based on criteria used in the prelicensure trials of aIIV3 and HD-IIV3: none (grade 0) mild (grade 1), moderate (grade 2), or severe (grade 3)<sup><xref rid="zoi200977r12" ref-type="bibr">12</xref>,<xref rid="zoi200977r13" ref-type="bibr">13</xref></sup> (see eAppendix 2 in <xref ref-type="supplementary-material" rid="note-ZOI200977-1-s">Supplement 2</xref>). Study staff contacted participants on day 3 and day 9 postvaccination to review solicited reactogenicity data, and assess for unsolicited adverse events, SAEs, AECI, and any new medical conditions or change in medications. Staff also monitored study participants for these outcomes, except for solicited reactogenicity, through day 43. SAEs were defined in accordance with the US Food and Drug Administration.<sup><xref rid="zoi200977r25" ref-type="bibr">25</xref></sup> AECIs were syncope during postvaccination monitoring in clinic, anaphylaxis within 24 hours after vaccination, and new-onset, immune-mediated conditions (including Guillain-Barré Syndrome) through day 43. Study investigators assessed relatedness of SAEs or AECI to the study vaccines.</p>
              </sec>
              <sec id="H2-3-ZOI200977">
                <title>Health-Related Quality of Life Assessment</title>
                <p>Study staff assessed HRQOL prevaccination on day 1 (in clinic) and on day 3 (by phone or in person) using the EuroQol 5 Dimensions-5 Level (EQ-5D-5L) and EQ Visual Analogue Scale (EQ-VAS) (2017-2018 and 2018-2019 influenza seasons) and the Late-Life Function &amp; Disability Instrument–Computer Adaptive Test (LLFDI-CAT) (2017-2018 influenza season only).<sup><xref rid="zoi200977r26" ref-type="bibr">26</xref>,<xref rid="zoi200977r27" ref-type="bibr">27</xref>,<xref rid="zoi200977r28" ref-type="bibr">28</xref></sup> The EQ-5D-5L is a standardized, generic measure of health status that provides information about HRQOL and activities of daily living relevant to older adults: mobility, self-care, usual activities, pain or discomfort, and anxiety or depression.<sup><xref rid="zoi200977r26" ref-type="bibr">26</xref>,<xref rid="zoi200977r27" ref-type="bibr">27</xref></sup> The EQ-VAS is a visual analogue scale from 0 to 100 that measures the respondent’s self-rated health.<sup><xref rid="zoi200977r26" ref-type="bibr">26</xref></sup> The LLFDI-CAT is a questionnaire assessing function (ability to perform discrete actions or activities as part of daily routines) and disability (socially-defined tasks) in community-dwelling older adults.<sup><xref rid="zoi200977r28" ref-type="bibr">28</xref></sup></p>
              </sec>
              <sec id="H2-4-ZOI200977">
                <title>Outcome Measures</title>
                <p>The primary outcome was comparison of proportions of participants with moderate-to-severe injection-site pain during days 1 to 8. We selected pain as the primary outcome because injection-site pain would be causally related to the vaccine, it was reported for both vaccines in prelicensure trials,<sup><xref rid="zoi200977r12" ref-type="bibr">12</xref>,<xref rid="zoi200977r13" ref-type="bibr">13</xref></sup> and pain that leads to a limitation (moderate) or complete inability (severe) to perform normal daily activities is clinically meaningful. We hypothesized that the proportion of participants with moderate-to-severe pain after aIIV3 would be noninferior to that after HD-IIV3. aIIV3 was the first adjuvanted influenza vaccine used in the US.<sup><xref rid="zoi200977r13" ref-type="bibr">13</xref></sup> HD-IIV3 was selected as the comparator because at the time of our study, it was widely used, with substantive evidence supporting its safety.<sup><xref rid="zoi200977r29" ref-type="bibr">29</xref>,<xref rid="zoi200977r30" ref-type="bibr">30</xref></sup> The coprimary outcome was comparison of the frequencies of SAEs and AECI in the 2 treatment groups. Secondary outcomes included a comparison of postvaccination moderate-to-severe local and systemic reactions during days 1 to 8, and before (day 1) vs after vaccination (day 3) changes in EQ-5D-5L utility index, EQ-VAS, and LLFDI-CAT scores. We also assessed the above outcomes after aIIV3 and HD-IIV3 by age group (aged 65-79 years and ≥80 years).</p>
              </sec>
              <sec id="H2-5-ZOI200977">
                <title>Statistical Analysis</title>
                <p>The planned sample size of at least 668 evaluable participants (334 per group across all sites) provided at least 80% power to reject the null hypothesis that the proportion of participants with moderate-to-severe injection-site pain after aIIV3 is inferior to HD-IIV3 during days 1 to 8 (US Food and Drug Administration package inserts). Anticipating dropout, the study aimed to enroll at least 720 participants. The statistical testing for the primary outcome was conducted at the 1-sided α = .025 level using the upper bound of a stratified by site Newcombe binomial confidence interval<sup><xref rid="zoi200977r31" ref-type="bibr">31</xref></sup> with Cochran-Mantel-Haenszel (CMH) weighting with a noninferiority margin of 5%. The statistical method above was also used for the secondary comparison of the difference in proportions of moderate-to-severe local and systemic reactions between allV3 and HD-IIV3 groups, with a 1-sided α = 0.01 significance level to adjust for multiple comparisons. The reactogenicity comparisons were made using the full analysis population 1 that consisted of all participants who were randomized, vaccinated, and provided at least 1 day of complete data on the symptom diary form. The comparison of the frequencies of SAEs and AECI in the 2 treatment groups was made using exact binomial 95% CIs. The comparisons of at least 1 severe local and/or systemic reaction were made using the full analysis population 1 with a Fisher exact test. The changes in HRQOL after allV3 and HD-IIV3 administration were evaluated using Mann-Whitney <italic>U</italic> tests. These comparisons were made using the full analysis population 2 that consisted of all participants who were randomized and vaccinated. For the HRQOL comparisons, we used a 2-sided α = .01 level in the study population and α = .05 level for age-group analyses, which were considered exploratory. These data were analyzed using SASstatistical software version 9.4 (SAS Institute). Statistical analysis was performed from August 2019 to August 2020.</p>
              </sec>
            </sec>
            <sec id="H1-3-ZOI200977">
              <title>Results</title>
              <sec id="H2-6-ZOI200977">
                <title>Study Participants</title>
                <p>We assessed 778 participants for eligibility during 2 influenza seasons. Eight participants withdrew, and 13 additional participants did not meet eligibility criteria, yielding 757 randomized participants; 378 received aIIV3 and 379 received HD-IIV3 in full analysis population 2 (<xref ref-type="fig" rid="zoi200977f1">Figure 1</xref>). Of these 757 randomized participants, there were 420 women (55%) and 589 White individuals (78%) with a median (range) age of 72 (65-97) years. The baseline demographic and clinical characteristics of randomized participants were similar between the 2 study groups (<xref rid="zoi200977t1" ref-type="table">Table 1</xref>).</p>
                <fig id="zoi200977f1" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 1. </label>
                  <caption>
                    <title>Study Enrollment Flowchart</title>
                    <p>allV3 indicates trivalent adjuvanted inactivated influenza vaccine; and HD-IIV3, trivalent high-dose inactivated influenza vaccine.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2031266-g001"/>
                </fig>
                <table-wrap id="zoi200977t1" orientation="portrait" position="float">
                  <label>Table 1. </label>
                  <caption>
                    <title>Baseline Demographic and Clinical Characteristics of Participants in the Trivalent Adjuvanted Inactivated Influenza Vaccine and Trivalent High-Dose Inactivated Influenza Vaccine Groups</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="59.4%" span="1"/>
                    <col width="19.04%" span="1"/>
                    <col width="21.56%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Patients, No. (%)</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">aIIV3 (n = 378)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">HD-IIV3 (n = 379)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Study site</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Duke</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">214 (56.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">214 (56.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Boston</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">121 (32.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">122 (32.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cincinnati</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">43 (11.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">43 (11.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Influenza season of enrollment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2017-2018</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">138 (49.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">141 (50.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2018-2019</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">240 (50.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">238 (49.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, median (range), y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">72 (65-96)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">72 (65-97)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age group, y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 65-79</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">298 (78.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">296 (78.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ≥80</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">80 (21.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">83 (21.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Female</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">213 (56.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">207 (54.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">286 (75.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">303 (79.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">70 (18.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">59 (15.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asian</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (1.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (1.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<xref ref-type="table-fn" rid="zoi200977t1n1"><sup>a</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">17 (4.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 (3.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hispanic ethnicity</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (1.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Education, some college or higher</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">328 (86.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">331 (87.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Employment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Employed</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">62 (16.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">64 (16.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Retired</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">300 (79.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">300 (79.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> None</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14 (3.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Living alone</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">151 (39.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">148 (39.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Cardiovascular and respiratory disorders<xref ref-type="table-fn" rid="zoi200977t1n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Atrial fibrillation</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">29 (7.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22 (5.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Coronary artery disease</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">28 (7.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 (7.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Heart failure</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (6.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 (3.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hyperlipidemia</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">137 (36.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">151 (39.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hypertension</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">83 (22.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">71 (18.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valvular heart disease</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">17 (4.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 (2.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asthma</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (1.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (2.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chronic obstructive pulmonary disease</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (1.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Other common conditions</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Arthritis</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">73 (19.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">75 (19.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Depression</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">50 (13.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">49 (12.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Diabetes</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (6.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 (7.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Gastroesophageal reflux disease</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">39 (10.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (6.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hearing loss</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (2.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16 (4.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hypothyroidism</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">38 (10.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">34 (9.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Statin use</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">184 (48.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">177 (46.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Received influenza vaccine in the previous season<xref ref-type="table-fn" rid="zoi200977t1n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">276 (73.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">279 (73.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Prevaccination, mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> EuroQol 5 Dimensions-5 Level<xref ref-type="table-fn" rid="zoi200977t1n4"><sup>d</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.89 (0.118)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.90 (0.130)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> EuroQol Visual Analogue Scale<xref ref-type="table-fn" rid="zoi200977t1n5"><sup>e</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">85.5 (13.672)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">85.8 (12.506)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: aIIV3, trivalent adjuvanted inactivated influenza vaccine; HD-IIV3, trivalent high-dose inactivated influenza.</p>
                    <fn id="zoi200977t1n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Other races include American Indian/Alaskan Native, Asian, and more than 1 race.</p>
                    </fn>
                    <fn id="zoi200977t1n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>These conditions are not mutually exclusive.</p>
                    </fn>
                    <fn id="zoi200977t1n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Determined by medical records or self-report.</p>
                    </fn>
                    <fn id="zoi200977t1n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>The score is a utility index that ranges from −0.109 (worst health) to 1.000 (best health) for US-specific values.</p>
                    </fn>
                    <fn id="zoi200977t1n5">
                      <label>
                        <sup>e</sup>
                      </label>
                      <p>EuroQol Visual Analogue Scale measures self-rated health with a score that ranges from 0 to 100, with 100 equal to the “best health you can imagine” and 0 equal “to the worst health you can imagine.”</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>We randomized 279 participants in 2017 to 2018 and 478 participants in 2018 to 2019. No study participant received study vaccines more than once in successive years. For full analysis population 1, 378 received aIIV3 and 377 received HD-IIV3 because 2 participants were missing symptom diary data (<xref ref-type="fig" rid="zoi200977f1">Figure 1</xref>).</p>
              </sec>
              <sec id="H2-7-ZOI200977">
                <title>Safety and Reactogenicity</title>
                <p>The proportion of participants reporting moderate-to-severe injection-site pain after aIIV3 (12 patients [3.2%]) was noninferior to (ie, not higher than) the proportion of patients reporting pain after receiving HD-IIV3 (22 patients [5.8%]) (difference, −2.7%; 95% CI, −5.8% to 0.4%) (<xref rid="zoi200977t2" ref-type="table">Table 2</xref> and <xref ref-type="fig" rid="zoi200977f2">Figure 2</xref>). The difference of proportions (aIIV3 minus HD-IIV3) of moderate-to-severe reactions for 4 solicited symptoms (injection-site tenderness, arthralgia, fatigue, and malaise) did not meet noninferiority criteria for aIIV3 (<xref rid="zoi200977t2" ref-type="table">Table 2</xref> 5.8%<xref ref-type="fig" rid="zoi200977f2">Figure 2</xref>). These findings are inconclusive because the confidence intervals include the noninferiority margin and do not exclude 0.<sup><xref rid="zoi200977r32" ref-type="bibr">32</xref></sup> aIIV3 was noninferior to HD-IIV3 for the remaining 10 moderate-to-severe solicited reactions (<xref rid="zoi200977t2" ref-type="table">Table 2</xref> 5.8%<xref ref-type="fig" rid="zoi200977f2">Figure 2</xref>). We observed clinically similar patterns of moderate-to-severe systemic reactions in the full study population (<xref rid="zoi200977t2" ref-type="table">Table 2</xref>) and in the age groups for both 65 to 79 years and at least 80 years (eTable in <xref ref-type="supplementary-material" rid="note-ZOI200977-1-s">Supplement 2</xref>). In the 163 participants aged 80 years or older, the proportion of participants with moderate-to-severe reactions were low and no clinically meaningful differences were observed between the 2 vaccine groups.</p>
                <table-wrap id="zoi200977t2" orientation="portrait" position="float">
                  <label>Table 2. </label>
                  <caption>
                    <title>Local and Systemic Reactions During Days 1 Through 8 Following Trivalent Adjuvanted Inactivated Influenza Vaccine and Trivalent High-Dose Inactivated Influenza in Older Adults</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="39.78%" span="1"/>
                    <col width="15.54%" span="1"/>
                    <col width="15.54%" span="1"/>
                    <col width="29.14%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Reactions</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Patients, No. (%)</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Proportion difference (aIIV3 – HD-IIV3), % (95% CI)<xref ref-type="table-fn" rid="zoi200977t2n1"><sup>a</sup></xref></th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">aIIV3 (n = 378)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">HD-IIV3 (n = 377)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="4" valign="top" align="left" scope="col" rowspan="1">Local</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Injection-site pain</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">81 (21.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">95 (25.2)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">−2.7 (−5.8 to 0.4)<xref ref-type="table-fn" rid="zoi200977t2n4"><sup>d</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (2.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">21 (5.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 (3.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22 (5.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Tenderness</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">177 (46.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">181 (48.0)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">1.6 (−2.7 to 5.9)<xref ref-type="table-fn" rid="zoi200977t2n5"><sup>e</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">24 (6.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">20 (5.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 (7.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">21 (5.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Swelling</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">43 (11.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">49 (13.0)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">−3.7 (−7.5 to −0.25)<xref ref-type="table-fn" rid="zoi200977t2n4"><sup>d</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (1.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">20 (5.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9 (2.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (6.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Redness</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30 (7.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">36 (9.5)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">−1.9 (−5.0 to 1.0)<xref ref-type="table-fn" rid="zoi200977t2n4"><sup>d</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (1.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9 (2.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (1.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (1.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 (3.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Shoulder pain on side of vaccination</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">61 (16.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">51 (13.5)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">0.5 (−3.1 to 4.3)<xref ref-type="table-fn" rid="zoi200977t2n4"><sup>d</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14 (3.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14 (3.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">17 (4.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (4.0)</td>
                      </tr>
                      <tr>
                        <td colspan="4" valign="top" align="left" scope="col" rowspan="1">Systemic</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Fatigue</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">59 (15.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">40 (10.6)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">3.2 (−0.1 to 7.3)<xref ref-type="table-fn" rid="zoi200977t2n5"><sup>e</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">24 (6.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 (3.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 (7.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (4.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Malaise</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">46 (12.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">33 (8.8)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">1.8 (−1.6 to 5.4)<xref ref-type="table-fn" rid="zoi200977t2n5"><sup>e</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (4.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (1.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (1.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">18 (4.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 (3.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Myalgia</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">44 (11.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">39 (10.3)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">0.5 (−3.3 to 4.4)<xref ref-type="table-fn" rid="zoi200977t2n4"><sup>d</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16 (4.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (4.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">19 (5.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">17 (4.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Headache</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">43 (11.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">39 (10.3)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">−0.3 (−3.0 to 2.4)<xref ref-type="table-fn" rid="zoi200977t2n4"><sup>d</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (1.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (1.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (1.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (2.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Arthralgia</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">38 (10.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31 (8.2)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">1.8 (−1.7 to 5.4)<xref ref-type="table-fn" rid="zoi200977t2n5"><sup>e</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14 (3.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (2.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (1.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">18 (4.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 (2.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Nausea</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">21 (5.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (4.0)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">−0.8 (−3.1 to 1.6)<xref ref-type="table-fn" rid="zoi200977t2n4"><sup>d</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (1.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Diarrhea</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">20 (5.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">18 (4.8)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">−1.1 (−4.0 to 1.5)<xref ref-type="table-fn" rid="zoi200977t2n4"><sup>d</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (1.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (2.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (1.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9 (2.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Vomiting</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (1.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">0.0 (−1.8 to 1.8)<xref ref-type="table-fn" rid="zoi200977t2n4"><sup>d</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Chills</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16 (4.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14 (3.7)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">−0.5 (−2.8 to 2.3)<xref ref-type="table-fn" rid="zoi200977t2n4"><sup>d</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (1.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (1.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Fever</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 (3.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (4.0)</td>
                        <td rowspan="4" valign="middle" align="left" colspan="1">0.5 (−2.5 to 2.0)<xref ref-type="table-fn" rid="zoi200977t2n4"><sup>d</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate<xref ref-type="table-fn" rid="zoi200977t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Severe<xref ref-type="table-fn" rid="zoi200977t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Moderate-to-severe</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: aIIV3, trivalent adjuvanted inactivated influenza vaccine; HD-IIV3, trivalent high-dose inactivated influenza.</p>
                    <fn id="zoi200977t2n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Proportion difference of aIIV3 minus HD-IIV3 for moderate-to-severe reactions and 95% CI. Analysis of proportion difference of aIIV3 minus HD-IIV3 for moderate-to-severe reactions was the objective of the study. Analysis of differences for any, moderate alone and severe alone was not done because these were not objectives of the study.</p>
                    </fn>
                    <fn id="zoi200977t2n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Moderate swelling and redness was considered 25 mm to less than 50 mm; moderate fever was considered more than 38 °C but less than 39 °C; all other reactions, moderate was considered some limitation in normal daily activity.</p>
                    </fn>
                    <fn id="zoi200977t2n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Severe swelling and redness was considered at least 50 mm; moderate fever was considered higher than 39 °C; all other reactions, severe was considered completely unable to perform normal daily activity.</p>
                    </fn>
                    <fn id="zoi200977t2n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Inferiority hypothesis was rejected and noninferiority is concluded.</p>
                    </fn>
                    <fn id="zoi200977t2n5">
                      <label>
                        <sup>e</sup>
                      </label>
                      <p>Inferiority hypothesis was not rejected and noninferiority cannot be concluded.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig id="zoi200977f2" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 2. </label>
                  <caption>
                    <title>Difference in Trivalent Adjuvanted Inactivated Influenza Vaccine (aIIV3) vs Trivalent High-Dose Inactivated Influenza Vaccine (HD-IIV3) Reactions</title>
                    <p>Circles denote means and error bars denote 98% CIs except for injection-site pain, for which a 95% CI is shown. Dashed lines at 0% denote no difference; dashed lines at 5% denote the noninferiority margin.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2031266-g002"/>
                </fig>
                <p>At least 1 severe local reaction occurred in 3.7% of aIIV3 recipients and 2.9% HD-IIV3 recipients. At least 1 severe systemic reaction occurred in 2.1% of aIIV3 recipients and 1.6% of HD-IIV3 recipients. At least 1 severe local or systemic reaction occurred in 4.8% of aIIV3 recipients and 4.0% HD-IIV3 recipients. No participant sought medical attention for a local or systemic reaction after vaccination on days 1 to 8.</p>
                <p>There were no episodes of syncope during postvaccination monitoring in the clinic or anaphylaxis within 24 hours of vaccination. During the 43-day follow-up period, there were no deaths, episodes of Guillain-Barré syndrome, or new-onset immune-mediated conditions. Nine participants had at least 1 SAE after aIIV3 (2.4%; 95% CI,1.1%-4.5%); 3 participants had at least 1 SAE after HD-IIV3 (0.8%; 95% CI, 0.2%-2.2%) (<xref rid="zoi200977t3" ref-type="table">Table 3</xref>). Study investigators assessed no SAE to be associated with vaccination and observed no clinical imbalances between study groups.</p>
                <table-wrap id="zoi200977t3" orientation="portrait" position="float">
                  <label>Table 3. </label>
                  <caption>
                    <title>Older Adult Participants Experiencing Serious Adverse Events During Days 1 Through 43 Following Trivalent Adjuvanted Inactivated Influenza Vaccine and Trivalent High-Dose Inactivated Influenza<xref ref-type="table-fn" rid="zoi200977t3n1"><sup>a</sup></xref></title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="20.76%" span="1"/>
                    <col width="17.08%" span="1"/>
                    <col width="17.08%" span="1"/>
                    <col width="45.08%" span="1"/>
                    <thead>
                      <tr>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Group, time since vaccination, d</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Age group, y</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">SAE description</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">aIIV3</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 22</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Male</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65-79</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Pulmonary emboli</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 23</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Female</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65-79</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Fall</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 24</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Male</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65-79</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Small bowel obstruction</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 27</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Female</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65-79</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Respiratory failure<xref ref-type="table-fn" rid="zoi200977t3n2"><sup>b</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 27</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Female</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65-79</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Asthma exacerbation and congestive heart failure</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 29</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Female</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65-79</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Stress-induced cardiomyopathy</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 29</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Female</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65-79</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Transient ischemic attack</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 34</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Male</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">≥80</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Fall</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 34</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Male</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65-79</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Near syncope due to orthostasis</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">HD-IIV3</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 11</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Male</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">≥80</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Chest pain</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 18</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Female</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65-79</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Postoperative ileus</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 39</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Male</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">≥80</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Metastatic squamous cell carcinoma<xref ref-type="table-fn" rid="zoi200977t3n2"><sup>b</sup></xref></td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: aIIV3, trivalent adjuvanted inactivated influenza vaccine; HD-IIV3, trivalent high-dose inactivated influenza; SAE, serious adverse events.</p>
                    <fn id="zoi200977t3n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>None of the SAEs was judged to be causally related to receipt of vaccine.</p>
                    </fn>
                    <fn id="zoi200977t3n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Patient died from complications of SAE and underlying health comorbidities more than 43 days after vaccination.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="H2-8-ZOI200977">
                <title>HRQOL Scores</title>
                <p>Participants’ baseline prevaccination HRQOL scores were similar in both study groups (<xref rid="zoi200977t1" ref-type="table">Table 1</xref>). Change in EQ-5D-5L utility index score from day 1 (before vaccination) to Day 3 postvaccination was not significantly different between treatment groups (−0.05 aIIV3 vs −0.05 HD-IIV3), nor was change in EQ VAS (−2.22 aIIV3 vs −2.49 HD-IIV3), or change in LLFDI scores for activity limitation, daily activities, basic mobility, participation restriction, social roles, and instrumental roles. Changes in EQ-5D-5L utility index score, EQ-VAS, and LLFDI scores from day 1 to day 3 postvaccination were not significantly different between treatment groups in the exploratory analyses by age group (65-79 years and ≥80 years), with the exception of the LLFDI changes in social roles scores in participants aged 65 to 79 years (−0.66 aIIV3 vs −1.98 HD-IIV3; difference, −1.32; <italic>P</italic> = .04).</p>
              </sec>
            </sec>
            <sec id="H1-4-ZOI200977">
              <title>Discussion</title>
              <p>To our knowledge, this is the first randomized clinical trial in the US directly comparing the safety, reactogenicity, and short-term quality of life following vaccination with aIIV3 or HD-IIV3 in older adults. Consistent with the study hypothesis, we found that the proportions of participants with moderate-to-severe injection-site pain after vaccination with aIIV3 was noninferior (not higher) vs HD-IIV3. Ten reactions met noninferiority criteria for aIIV3; 4 (moderate-to-severe injection-site tenderness, arthralgia, fatigue, and malaise) did not. It was inconclusive whether these 4 reactions occurred in higher proportions of participants.<sup><xref rid="zoi200977r32" ref-type="bibr">32</xref></sup> Few (4.8% of aIIV3 recipients and 4.0% HD-IIV3 recipients) individuals experienced any severe reaction after either vaccine in our study. No reactions led to a medical visit. We observed no vaccine-related SAEs or AECI, including no new-onset immune-mediated disease within 43 days after aIIV3 or HD-IIV3 vaccination.</p>
              <p>Safety profiles of aIIV3 and HD-IIV3 in our study were consistent with those found in prelicensure studies for each vaccine. The proportions of individuals with moderate-to-severe injection-site pain were 4.2% of aIIV3 recipients and 4.0% of HD-IIV3 recipients in prelicensure studies,<sup><xref rid="zoi200977r12" ref-type="bibr">12</xref>,<xref rid="zoi200977r13" ref-type="bibr">13</xref></sup> compared with 3.2% and 5.8%, respectively, in our study. Moderate-to-severe injection-site tenderness after aIIV3 was 4% higher in our study than in prelicensure aIIV3 studies<sup><xref rid="zoi200977r13" ref-type="bibr">13</xref></sup>; injection-site swelling after HD-IIV3 was 3% higher in our study than in prelicensure studies.<sup><xref rid="zoi200977r12" ref-type="bibr">12</xref></sup> Prelicensure studies compared reactogenicity and safety of aIIV3 and HD-IIV3 to SD-IIV3.<sup><xref rid="zoi200977r12" ref-type="bibr">12</xref>,<xref rid="zoi200977r13" ref-type="bibr">13</xref></sup></p>
              <p>In a postlicensure study in Hong Kong, Cowling et al<sup><xref rid="zoi200977r33" ref-type="bibr">33</xref></sup> assessed reactogenicity and safety outcomes in older adults receiving aIIV3 (508 patients) or HD-IIV3 (510 patients). Similar to our study, the most commonly reported reactions were injection-site pain and tenderness. Proportions of any and moderate-to-severe reactions at 1 to 2 days after aIIV3 or HD-IIV3 were generally lower than in our study. Hospitalization rates less than or equal to 30 days after vaccination were similar between aIIV3 (0.6%) and HD-IIV3 (1%). Investigators identified no vaccine-related SAEs.<sup><xref rid="zoi200977r33" ref-type="bibr">33</xref></sup></p>
              <p>In a recently published study from Australia,<sup><xref rid="zoi200977r34" ref-type="bibr">34</xref></sup> the AusVaxSafety postlicensure active surveillance program analyzed text responses from more than 47 000 persons aged at least 65 years who received aIIV3 or HD-IIV3. Injection-site pain was the most frequently reported solicited adverse event (2.1% for HD-IIV3 and 1.3% for aIIV3). Rates of medical attention (used as a proxy for serious AEs) were low for both HD-IIV3 and aIIV3 (0.3%). Similar to our study, results of this comparative safety study of aIIV3 and HD-IIV3 in older adults were reassuring.</p>
              <p>For older persons, any reaction that limits or prevents activities of daily living may have a substantial impact on quality of life. In our study, we measured quality of life change from baseline to 2 days postvaccination using HRQOL instruments validated for older adults. We found no significant differences in the change of prevaccination vs postvaccination HRQOL scores between the aIIV3 and HD-IIV3 groups. Changes in scores from prevaccination to 2 days postvaccination in each group were small, and clinically not meaningful. To our knowledge, our study is the first clinical trial to assess postvaccination HRQOL effects in adults receiving aIIV3 or HD-IIV3 vaccines.</p>
              <sec id="H2-9-ZOI200977">
                <title>Limitations</title>
                <p>This study has several limitations. First, our study was powered for a single outcome of injection-site pain, but the study was not powered for other reactions or study outcomes. In addition, the study population was drawn from a population of community-dwelling older adults, who were highly educated and had high self-rated health. Postvaccination HRQOL and VAS within group and between groups might have been different if study participants resided in assisted living facilities or had lower baseline HRQOL and VAS scores. Also, our study does not address safety of administering aIIV3 or HD-IIV3 with other vaccines at the same visit.</p>
                <p>The safety of adjuvanted influenza vaccines has been a topic of public interest.<sup><xref rid="zoi200977r35" ref-type="bibr">35</xref></sup> We found that our primary outcome of moderate-to-severe injection-site pain after aIIV3 was not worse than HD-IIV3. Of the 14 other reactions assessed as secondary outcomes, 10 (including fever), were not higher after aIIV3 than HD-IIV3. Our study findings are inconclusive as to whether the proportion of participants with injection-site tenderness and 3 other reactions were significantly higher after aIIV3, compared with HD-IIV3, suggesting that our study was underpowered for these secondary reactogenicity outcomes.<sup><xref rid="zoi200977r32" ref-type="bibr">32</xref></sup> The findings that no reaction led to a medical visit in either group and that there was not an important impact on short-term quality of life after vaccination lends further support to the safety of both vaccines. Similar clinical safety profiles support the conclusion that concerns about differences in safety between aIIV3 and HD-IIV3 need not be a factor when choosing between them.</p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI200977">
              <title>Conclusions</title>
              <p>In our trial comparing aIIV3 and HD-IIV3 in older adults, no vaccine-related SAEs occurred and safety findings were consistent with prelicensure data. The proportion of participants with moderate-to-severe injection-site pain was not higher after aIIV3 than HD-IIV3. Postvaccination HRQOL was similar. From the standpoint of safety, our study’s results suggest that either vaccine is an acceptable option to prevent influenza in older adults.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI200977">
              <title>References</title>
              <ref id="zoi200977r1">
                <label>1</label>
                <mixed-citation publication-type="web"><person-group><collab>Centers for Disease Control and Prevention</collab></person-group> FluView–Outpatient Illness Surveillance. Hospitalization in older adults. Published <year>2018</year> Accessed October 26, 2019. <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/weekly">https://www.cdc.gov/flu/weekly</ext-link></mixed-citation>
              </ref>
              <ref id="zoi200977r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><collab>Centers for Disease Control and Prevention (CDC)</collab></person-group><article-title>Estimates of deaths associated with seasonal influenza—United States, 1976-2007</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2010</year>;<volume>59</volume>(<issue>33</issue>):<fpage>1057</fpage>-<lpage>1062</lpage>.<?supplied-pmid 20798667?><pub-id pub-id-type="pmid">20798667</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Covinsky</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Palmer</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Fortinsky</surname><given-names>RH</given-names></name>, <etal/></person-group><article-title>Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age</article-title>. <source>J Am Geriatr Soc</source>. <year>2003</year>;<volume>51</volume>(<issue>4</issue>):<fpage>451</fpage>-<lpage>458</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1532-5415.2003.51152.x</pub-id><?supplied-pmid 12657063?><pub-id pub-id-type="pmid">12657063</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Kwong</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Campitelli</surname><given-names>MA</given-names></name>, <etal/></person-group><article-title>Acute myocardial infarction after laboratory-confirmed influenza infection</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>378</volume>(<issue>4</issue>):<fpage>345</fpage>-<lpage>353</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1702090</pub-id><?supplied-pmid 29365305?><pub-id pub-id-type="pmid">29365305</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Mullooly</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Bridges</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>WW</given-names></name>, <etal/>; <collab>Vaccine Safety Datalink Adult Working Group</collab></person-group><article-title>Influenza- and RSV-associated hospitalizations among adults</article-title>. <source>Vaccine</source>. <year>2007</year>;<volume>25</volume>(<issue>5</issue>):<fpage>846</fpage>-<lpage>855</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.09.041</pub-id><?supplied-pmid 17074423?><pub-id pub-id-type="pmid">17074423</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Pereira</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Gilca</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Waite</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Andrew</surname><given-names>MK</given-names></name></person-group><article-title>Canadian older adults’ perceptions of effectiveness and value of regular and high-dose influenza vaccines</article-title>. <source>Hum Vaccin Immunother</source>. <year>2019</year>;<volume>15</volume>(<issue>2</issue>):<fpage>487</fpage>-<lpage>495</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2018.1520580</pub-id><?supplied-pmid 30204043?><pub-id pub-id-type="pmid">30204043</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Reed</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chaves</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Daily Kirley</surname><given-names>P</given-names></name>, <etal/></person-group><article-title>Estimating influenza disease burden from population-based surveillance data in the United States</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>3</issue>):<elocation-id>e0118369</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0118369</pub-id><?supplied-pmid 25738736?><pub-id pub-id-type="pmid">25738736</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Thompson</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Shay</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Weintraub</surname><given-names>E</given-names></name>, <etal/></person-group><article-title>Mortality associated with influenza and respiratory syncytial virus in the United States</article-title>. <source>JAMA</source>. <year>2003</year>;<volume>289</volume>(<issue>2</issue>):<fpage>179</fpage>-<lpage>186</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.289.2.179</pub-id><?supplied-pmid 12517228?><pub-id pub-id-type="pmid">12517228</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Warren-Gash</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hayward</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Hemingway</surname><given-names>H</given-names></name>, <etal/></person-group><article-title>Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study</article-title>. <source>J Infect Dis</source>. <year>2012</year>;<volume>206</volume>(<issue>11</issue>):<fpage>1652</fpage>-<lpage>1659</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jis597</pub-id><?supplied-pmid 23048170?><pub-id pub-id-type="pmid">23048170</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Viboud</surname><given-names>CG</given-names></name>, <etal/></person-group><article-title>Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008</article-title>. <source>Clin Infect Dis</source>. <year>2012</year>;<volume>54</volume>(<issue>10</issue>):<fpage>1427</fpage>-<lpage>1436</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/cis211</pub-id><?supplied-pmid 22495079?><pub-id pub-id-type="pmid">22495079</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Grohskopf</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Alyanak</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Broder</surname><given-names>KR</given-names></name>, <etal/></person-group><article-title>Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices—United States, 2020-21 influenza season</article-title>. <source>MMWR Recomm Rep</source>. <year>2020</year>;<volume>69</volume>(<issue>8</issue>):<fpage>1</fpage>-<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.rr6908a1</pub-id><?supplied-pmid 32820746?><pub-id pub-id-type="pmid">32820746</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r12">
                <label>12</label>
                <mixed-citation publication-type="web"><person-group><collab>Sanofi Pasteur</collab></person-group> FLUZONE<sup>®</sup> High-Dose. US package insert. Published March 29, <year>2019</year> Accessed August 29, 2019. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/119870/download">https://www.fda.gov/media/119870/download</ext-link></mixed-citation>
              </ref>
              <ref id="zoi200977r13">
                <label>13</label>
                <mixed-citation publication-type="web"><person-group><collab>Seqirus Inc</collab></person-group> FLUAD<sup>®</sup> US package insert. Published October 14, <year>2020</year> Accessed October 21, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/94583/download">https://www.fda.gov/media/94583/download</ext-link></mixed-citation>
              </ref>
              <ref id="zoi200977r14">
                <label>14</label>
                <mixed-citation publication-type="web"><person-group><collab>Sanofi Pasteur</collab></person-group> FLUZONE<sup>®</sup> High-Dose Quadrivalent. US package insert. Published <year>2019</year> Accessed August 20, 2019. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/132238/download">https://www.fda.gov/media/132238/download</ext-link></mixed-citation>
              </ref>
              <ref id="zoi200977r15">
                <label>15</label>
                <mixed-citation publication-type="web"><person-group><collab>Seqirus Inc</collab></person-group> FLUAD<sup>®</sup> Quadrivalent. US package insert. Published October 14, <year>2020</year> Accessed October 21, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/135432/download">https://www.fda.gov/media/135432/download</ext-link></mixed-citation>
              </ref>
              <ref id="zoi200977r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Chang</surname><given-names>L-J</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Janosczyk</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Landolfi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Talbot</surname><given-names>HK</given-names></name>; <collab>QHD00013 Study Group</collab></person-group><article-title>Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: a phase 3 randomized clinical trial</article-title>. <source>Vaccine</source>. <year>2019</year>;<volume>37</volume>(<issue>39</issue>):<fpage>5825</fpage>-<lpage>5834</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.08.016</pub-id><?supplied-pmid 31431411?><pub-id pub-id-type="pmid">31431411</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>DiazGranados</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Dunning</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Kimmel</surname><given-names>M</given-names></name>, <etal/></person-group><article-title>Efficacy of high-dose versus standard-dose influenza vaccine in older adults</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>(<issue>7</issue>):<fpage>635</fpage>-<lpage>645</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1315727</pub-id><?supplied-pmid 25119609?><pub-id pub-id-type="pmid">25119609</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Van Buynder</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Konrad</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Van Buynder</surname><given-names>JL</given-names></name>, <etal/></person-group><article-title>The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly</article-title>. <source>Vaccine</source>. <year>2013</year>;<volume>31</volume>(<issue>51</issue>):<fpage>6122</fpage>-<lpage>6128</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.07.059</pub-id><?supplied-pmid 23933368?><pub-id pub-id-type="pmid">23933368</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Izurieta</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Chillarige</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kelman</surname><given-names>J</given-names></name>, <etal/></person-group><article-title>Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017-2018</article-title>. <source>J Infect Dis</source>. <year>2019</year>;<volume>220</volume>(<issue>8</issue>):<fpage>1255</fpage>-<lpage>1264</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiy716</pub-id><?supplied-pmid 30561688?><pub-id pub-id-type="pmid">30561688</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Treanor</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Tornieporth</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Capellan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gorse</surname><given-names>GJ</given-names></name></person-group><article-title>Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older</article-title>. <source>J Infect Dis</source>. <year>2009</year>;<volume>200</volume>(<issue>2</issue>):<fpage>172</fpage>-<lpage>180</lpage>. doi:<pub-id pub-id-type="doi">10.1086/599790</pub-id><?supplied-pmid 19508159?><pub-id pub-id-type="pmid">19508159</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Frey</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Reyes</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Reynales</surname><given-names>H</given-names></name>, <etal/></person-group><article-title>Comparison of the safety and immunogenicity of an MF59<sup>®</sup>-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>39</issue>):<fpage>5027</fpage>-<lpage>5034</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.07.013</pub-id><?supplied-pmid 25045825?><pub-id pub-id-type="pmid">25045825</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r22">
                <label>22</label>
                <mixed-citation publication-type="web"><person-group><collab>US Centers for Disease Control and Prevention</collab></person-group> Clinical Immunization Safety Assessment (CISA) Project. Accessed August 8, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html">https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html</ext-link></mixed-citation>
              </ref>
              <ref id="zoi200977r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Borson</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Scanlan</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ganguli</surname><given-names>M</given-names></name></person-group><article-title>The Mini-Cog as a screen for dementia: validation in a population-based sample</article-title>. <source>J Am Geriatr Soc</source>. <year>2003</year>;<volume>51</volume>(<issue>10</issue>):<fpage>1451</fpage>-<lpage>1454</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1532-5415.2003.51465.x</pub-id><?supplied-pmid 14511167?><pub-id pub-id-type="pmid">14511167</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Naqvi</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Haider</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tomlinson</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Alibhai</surname><given-names>S</given-names></name></person-group><article-title>Cognitive assessments in multicultural populations using the Rowland Universal Dementia Assessment Scale: a systematic review and meta-analysis</article-title>. <source>CMAJ</source>. <year>2015</year>;<volume>187</volume>(<issue>5</issue>):<fpage>E169</fpage>-<lpage>E175</lpage>. doi:<pub-id pub-id-type="doi">10.1503/cmaj.140802</pub-id><?supplied-pmid 25691786?><pub-id pub-id-type="pmid">25691786</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r25">
                <label>25</label>
                <mixed-citation publication-type="web"><person-group><collab>US Food and Drug Administration</collab></person-group> Code of Federal Regulations Title 21: 21 CFR Part 312 Section 32. Revised April 1, <year>2018</year> Accessed August 29, 2019. <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=600.80">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=600.80</ext-link></mixed-citation>
              </ref>
              <ref id="zoi200977r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Brazier</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kind</surname><given-names>P</given-names></name></person-group><article-title>Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire</article-title>. <source>Qual Life Res</source>. <year>1993</year>;<volume>2</volume>(<issue>3</issue>):<fpage>169</fpage>-<lpage>180</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00435221</pub-id><?supplied-pmid 8401453?><pub-id pub-id-type="pmid">8401453</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Herdman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gudex</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lloyd</surname><given-names>A</given-names></name>, <etal/></person-group><article-title>Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)</article-title>. <source>Qual Life Res</source>. <year>2011</year>;<volume>20</volume>(<issue>10</issue>):<fpage>1727</fpage>-<lpage>1736</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11136-011-9903-x</pub-id><?supplied-pmid 21479777?><pub-id pub-id-type="pmid">21479777</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>McDonough</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>P</given-names></name>, <etal/></person-group><article-title>Development of the computer-adaptive version of the Late-Life Function and Disability Instrument</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2012</year>;<volume>67</volume>(<issue>12</issue>):<fpage>1427</fpage>-<lpage>1438</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/gls108</pub-id><?supplied-pmid 22546960?><pub-id pub-id-type="pmid">22546960</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Wilkinson</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Szwajcer</surname><given-names>A</given-names></name>, <etal/></person-group><article-title>Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis</article-title>. <source>Vaccine</source>. <year>2017</year>;<volume>35</volume>(<issue>21</issue>):<fpage>2775</fpage>-<lpage>2780</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.03.092</pub-id><?supplied-pmid 28431815?><pub-id pub-id-type="pmid">28431815</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Moro</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Arana</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cano</surname><given-names>M</given-names></name>, <etal/></person-group><article-title>Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010</article-title>. <source>Clin Infect Dis</source>. <year>2012</year>;<volume>54</volume>(<issue>11</issue>):<fpage>1608</fpage>-<lpage>1614</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/cis256</pub-id><?supplied-pmid 22441652?><pub-id pub-id-type="pmid">22441652</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Yan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>X.</given-names></name></person-group><article-title>Stratified Wilson and Newcombe confidence intervals for multiple binomial proportions</article-title>. <source>Statistics in Biopharmaceutical Research</source><year>2010</year>;<volume>2</volume>(<issue>3</issue>):<fpage>329</fpage>-<lpage>335</lpage>. doi:<pub-id pub-id-type="doi">10.1198/sbr.2009.0049</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Mauri</surname><given-names>L</given-names></name>, <name name-style="western"><surname>D’Agostino</surname><given-names>RB</given-names><suffix>Sr</suffix></name></person-group><article-title>Challenges in the design and interpretation of noninferiority trials</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>(<issue>14</issue>):<fpage>1357</fpage>-<lpage>1367</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMra1510063</pub-id><?supplied-pmid 28976859?><pub-id pub-id-type="pmid">28976859</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Cowling</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Perera</surname><given-names>RAPM</given-names></name>, <name name-style="western"><surname>Valkenburg</surname><given-names>SA</given-names></name>, <etal/></person-group><article-title>Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial</article-title>. <source>Clin Infect Dis.</source><year>2019</year>;<elocation-id>ciz1034</elocation-id>; [Epub ahead of print]. doi:<pub-id pub-id-type="doi">10.1093/cid/ciz1034</pub-id><?supplied-pmid 31828291?><pub-id pub-id-type="pmid">31828291</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Pillsbury</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Fathima</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Quinn</surname><given-names>HE</given-names></name>, <etal/></person-group><article-title>Comparative postmarket safety profile of adjuvanted and high-dose influenza vaccines in individuals 65 years or older</article-title>. <source>JAMA Netw Open</source>. <year>2020</year>;<volume>3</volume>(<issue>5</issue>):<elocation-id>e204079</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.4079</pub-id><?supplied-pmid 32369177?><pub-id pub-id-type="pmid">32369177</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200977r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Panatto</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Amicizia</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Arata</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Gasparini</surname><given-names>R</given-names></name></person-group><article-title>A comprehensive analysis of Italian web pages mentioning squalene-based influenza vaccine adjuvants reveals a high prevalence of misinformation</article-title>. <source>Hum Vaccin Immunother</source>. <year>2018</year>;<volume>14</volume>(<issue>4</issue>):<fpage>969</fpage>-<lpage>977</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2017.1407483</pub-id><?supplied-pmid 29172967?><pub-id pub-id-type="pmid">29172967</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI200977-1">
              <supplementary-material content-type="local-data" id="note-ZOI200977-1-s">
                <label>Supplement 1.</label>
                <caption>
                  <p>
                    <bold>Trial Protocol and Statistical Analysis Plan</bold>
                  </p>
                </caption>
                <media xlink:href="jamanetwopen-e2031266-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p><bold>eAppendix 1.</bold> Eligibility Criteria</p>
                  <p><bold>eAppendix 2.</bold> Reactogenicity Assessment</p>
                  <p><bold>eTable.</bold> Local and Systemic Reactions during Days 1 through 8 Following Trivalent Adjuvanted Inactivated Influenza Vaccine (aIIV3) and Trivalent High-Dose Inactivated Influenza Vaccine (HD-IIV3) by Age Group in Older Adults</p>
                </caption>
                <media xlink:href="jamanetwopen-e2031266-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>
                    <bold>Data Sharing Statement</bold>
                  </p>
                </caption>
                <media xlink:href="jamanetwopen-e2031266-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
